A5058009437- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Esophageal Cancer Research and Treatment
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- Cancer-related molecular mechanisms research
- Urological Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Cancer-related gene regulation
- Cancer, Hypoxia, and Metabolism
- Catalytic Processes in Materials Science
- Advanced Condensed Matter Physics
- 3D Printing in Biomedical Research
- Circular RNAs in diseases
- Bone Tissue Engineering Materials
- Advanced Sensor and Energy Harvesting Materials
- Urinary Bladder and Prostate Research
- Genetic factors in colorectal cancer
- Inflammatory mediators and NSAID effects
- Additive Manufacturing and 3D Printing Technologies
- Urinary Tract Infections Management
- Cancer Genomics and Diagnostics
- Magnetic and transport properties of perovskites and related materials
Tianjin Medical University
2015-2025
Second Hospital of Tianjin Medical University
2015-2025
Beijing Institute of Graphic Communication
2023-2024
Jiangnan University
2024
Fujian Medical University
2023
Shanghai Tunnel Engineering (China)
2022
Battery Park
2022
Northeast Agricultural University
2020-2021
Tianjin Hospital
2018-2019
Clinical Research Management
2018
Abstract Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding the FcγR on macrophages abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistance anti‐PD‐1 therapy. This single‐arm phase 2 trial (NCT04004221/CTR20170071) assessed safety, tolerability, efficacy tislelizumab in patients with PD‐L1‐positive urothelial carcinoma who progressed during/following platinum‐containing therapy had no...
Bacillus Calmette-Guérin (BCG) is the standard of care for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection tumor (TURBT). BCG in combination programmed cell death-1 (PD-1) inhibitors may yield greater anti-tumor activity compared either agent alone. CREST a phase III study evaluating efficacy and safety subcutaneous PD-1 inhibitor sasanlimab BCG-naive NMIBC. Eligible participants are randomized to receive plus (induction ± maintenance) or...
Gelatin was widely used as scaffold materials in 3D bio-printing due to its excellent bioactivity and availability especially that their arginine-glycine-aspartic acid (RGD) sequences could efficiently promote cell adhesion proliferation. In this study, an electroactive bio-printable hydrogel prepared through a two-step chemical cross-linking process. Specifically, residual free amino groups of methacrylated gelatin (GelMA) were cross-linked with the aldehyde dibenzaldehyde-terminated...
Background and objectiveCombinations of immune checkpoint inhibitors nab-paclitaxel have achieved significant therapeutic effects in the treatment advanced urothelial carcinoma. Our aim was to assess efficacy safety tislelizumab combined with low-dose patients muscle-invasive bladder cancer (MIBC).MethodsTRUCE-01 a single-arm phase 2 study that included 62 T2-4a N0/X M0 MIBC tumors predominant carcinoma histology. Eligible received three 21-d cycles intravenous 200 mg on day 1 plus 2,...
Abstract Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma muscle-invasive bladder cancer. This study evaluates the safety efficacy tislelizumab combined with low-dose extensive very high-risk (VHR) non-muscle-invasive cancer (NMIBC). Patients Methods: TRUCE-02 was a single-arm phase 2 trial that included 63 patients visually incomplete resection and/or high-volume high-grade T1 tumors (with or without situ), who...
793 Background: Interim results of the randomized phase II trial neoadjuvant tislelizumab +/- oral APL-1202 (nitroxoline) revealed promising pathological complete response (pCR) rates and met prespecified thresholds for study expansion (ASCO GU 2024). Here, we report final primary endpoint analysis this trial. Methods: Patients with cT2-T4aN0M0 urothelial cancer bladder based on local assessment, planned radical cystectomy (RC), ineligible or refusing cisplatin-based chemotherapy were...
<div>AbstractPurpose:<p>Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma muscle-invasive bladder cancer. This study evaluates the safety efficacy tislelizumab combined with low-dose extensive very high–risk non–muscle-invasive cancer.</p>Patients Methods:<p>TRUCE-02 was a single-arm phase II trial that included 63 patients visually incomplete resection and/or high-volume high-grade T1 tumors (with...
<p>Supplementary Figure S1. Schematic protocol diagram.</p>
<p>Supplementary Figure S2. Duration of complete response any disease.</p>
A growing body of evidence shows that circular RNAs (circRNAs) participate in tumor growth and metastasis also play crucial roles the treatment prognosis various cancers. In this article, we identified a novel circRNA, circSOBP (has_circ_0001633), based on results high-throughput RNA sequencing, its expression was subsequently validated via quantitative reverse transcription polymerase chain reaction bladder cancer (BCa) tissues cell lines. The association between clinicopathologic features...
Abstract Background Neoadjuvant chemotherapy followed by radical cystectomy (RC) is the standard of care for patients with muscle‐invasive bladder cancer (MIBC). However, treatment outcomes are suboptimal. Camrelizumab, a PD‐1 blockade, has shown benefits in several tumors. This study aimed to investigate efficacy and safety neoadjuvant camrelizumab combination gemcitabine plus cisplatin (GC) RC MIBC patients. Methods was multi‐center, single‐arm that enrolled clinical stage T2‐4aN0‐1M0,...
Puerarin is an isoflavone isolated from the medicinal plant Pueraria lobata. The purpose of this study was to antiinflammatory and antimatrix-degrading effects puerarin in a rat osteoarthritis (OA) model its protective on joints. OA established by anterior cruciate ligament transection (ACLT) surgery. Rats (n = 40) were divided into nontreated OA, + celecoxib (2.86 mg/kg), (50 100 control groups. Two weeks after surgical induction, administered gavage daily for 8 weeks. After weeks,...
Background: Bone morphogenic protein (BMP) and Wnt signaling pathway molecules play important roles in cytodifferentiation cell proliferation. We attempted to localize these the granular ameloblastoma. Materials methods: Four samples of paraffin‐embedded ameloblastoma with cells were studied. Immunohistochemistry was performed detect basement membrane type heparan sulfate (HS) (JM403), surface HS (10E4), heparanase, Wnt‐5a, Wnt‐2, β‐catenin, BMP‐4. Results: In all four samples, strong...
Metastasis-associated in colon cancer 1 (MACC1) has recently been identified as a novel independent prognostic indicator for metastasis occurrence, overall survival and cancer-free patients with other solid tumors. In this study, we investigated the role of MACC1 development progression renal pelvis carcinoma, form upper tract urothelial carcinomas. protein found cytoplasm well nucleus transitional epithelial cells normal immunohistochemical (IHC) assays. Quantitative IHC examinations...
Genome-wide association studies (GWAS) have identified a number of genetic variants associated with risk bladder cancer in populations European descent. Here, we assessed two these variants, rs11892031 (2q37.1 region) and rs401681 (5p15.33 Chinese case-control study, which included 367 cases 420 controls. We found that the AC genotype was remarkably decreased (adjusted odds ratio (OR), 0.27; 95% confidence interval (CI), 0.09–0.81; p = 0.019), compared AA rs11892031; CT/CC genotypes were...